Overview

Data as of December 07, 2019 02:26 am EST

Press Releases

Summary Toggle Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

November 11, 2019

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH : demonstrated that resmetirom treatment resulted in statistically significant reduction in hepatic fat measured non-invasively (magnetic resonance imaging-proton density
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

November 06, 2019

CONSHOHOCKEN, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: “Madrigal continued to execute its clinical development strategy in non-alcoholic steatohepatitis (NASH) and non-alcoholic
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

August 07, 2019

-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected for the Liver Meeting ® AASLD 2019 in Boston , November 2019 -- CONSHOHOCKEN, Pa. , Aug.

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf
May 19, 2016	PREM14A	A preliminary proxy statement relating to a merger or acquisition	Mergers & Acquisitions	0001047469-16-013282.rtf 0001047469-16-013282.xls 0001047469-16-013282.pdf